An engineered recombinase removes the HIV-1 provirus from patient-derived cells and reduces infection in humanized mice.
References
Finzi, D. et al. Nat. Med. 5, 512–517 (1999).
Karpinksi, J.H.I., Chemnitz, J. & Buchholz, F. Nat. Biotechnol. 34, 401–409 (2016).
Archin, N.M. et al. Nature 487, 482–485 (2012).
Tebas, P. et al. N. Engl. J. Med. 370, 901–910 (2014).
Hütter, G. et al. N. Engl. J. Med. 360, 692–698 (2009).
Qu, X. et al. Nucleic Acids Res. 41, 7771–7782 (2013).
Ebina, H. et al. PLoS One 10, e0120047 (2015).
Hu, W. et al. Proc. Natl. Acad. Sci. USA 111, 11461–11466 (2014).
Kaminski, R. et al. Sci. Rep. 6, 22555 (2016).
Buchholz, F. & Stewart, A.F. Nat. Biotechnol. 19, 1047–1052 (2001).
Sarkar, I., Hauber, I., Hauber, J. & Buchholz, F. Science 316, 1912–1915 (2007).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Kim, M., Siliciano, R. Genome editing for clinical HIV isolates. Nat Biotechnol 34, 388–389 (2016). https://doi.org/10.1038/nbt.3531
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.3531
- Springer Nature America, Inc.